Breast Cancer Now media statements
We respond to new research into how salt in tumours could help diagnose and treat breast cancer
New research, funded by Breast Cancer Now and Cancer Research UK at the universities of York and Cambridge, has shown that analysing sodium ...
We respond to NICE provisional decision not to recommend alpelisib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to research about artificial sweeteners and breast cancer risk
Commenting on research published in PLOS Medicine about artificial sweeteners and breast cancer risk, Dr Kotryna Temcinaite, Senior Research...
We respond to new data from major trial OlympiA shows adjuvant olaparib improved survival in patients
On 16 March new findings from the OlympiA phase III trial were presented at a virtual plenary session from the European Society for Medical ...
We respond to NHS England's proposed new standards
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: January 2022
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to recommend breast cancer treatment tucatinib...
We respond to today's NHSE Breast Screening Programme 2020-21 report
Key findings: In 2020/21, around 936,000 fewer women in England were screened for breast cancer compared to the previous year. This is a dec...
We respond to the latest COVID-19 guidance
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
We respond to a new study looking at breast pain and breast cancer
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said: